NOTE: These studies represent individual publications using different populations of patients. Data are not directly comparable.

a Baseline values for patients with LAL-D in a clinical study; 32% [15/47] of pediatric patients <18 years of age and 58% [11/19] of adult patients ±18 years of age were on lipid-lowering medications [LLMs].2

b Data reported as mean and 95% Cl.9

c Data reported as median; 25th to 75th percentile, 2.0 to 3.0 mmol/L.10

NOTE: These studies represent individual publications using different populations of patients. Data are not directly comparable.

a Baseline values for patients with LAL-D in a clinical study; 32% [15/47] of pediatric patients <18 years of age and 58% [11/19] of adult patients ±18 years of age were on lipid-lowering medications [LLMs].2

b Metabolic syndrome was defined using previously published definitions.12,13

c LDL-c levels in African-American and Caucasian patients are shown in cohorts 1 and 2, respectively.12

d LDL-c levels in female and male patients are shown in cohorts 1 and 2, respectively.13

e Data reported as mean ±SE.12

REGISTER TODAY

and receive all the latest LAL-D information.

*All fields are required

THANK YOU
Your registration on LALDSource.com ensures that you will be among the first to receive news and updates about LAL-D.